Holen Sie sich die Stockscreener-App
6.26
2.19%
-0.14
Coya Therapeutics Inc Aktie (COYA) Neueste Nachrichten
Coya Therapeutics (NASDAQ:COYA) Now Covered by HC Wainwright - MarketBeat
Coya Therapeutics Announces Subcutaneously Administered COYA 302 Elicits Direct Anti-Inflammatory Effect in Brain in a Preclinical Inflammatory Mouse Model of Parkinson’s Disease - StockTitan
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Update - MarketBeat
Here's Why We're Not At All Concerned With Coya Therapeutics' (NASDAQ:COYA) Cash Burn Situation - Yahoo Finance
Coya Therapeutics to Present at Upcoming Healthcare Conferences - StockTitan
Coya Therapeutics promotes Arun Swaminathan to CEO post - The Pharma Letter
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer - citybiz
Coya Therapeutics appoints new CEO, founder shifts role - Investing.com
Coya Therapeutics Names Arun Swaminathan Chief Executive - MarketWatch
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - Manchestertimes
Coya Therapeutics Promotes Arun Swaminathan Ph.D. to Chief Executive Officer Effective November 1st, 2024 - StockTitan
Coya Therapeutics, Inc. (NASDAQ:COYA) to Post FY2024 Earnings of ($1.17) Per Share, Chardan Capital Forecasts - MarketBeat
Vanguard Group Inc. Has $8.41 Million Stake in Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat
Coya Therapeutics, Inc. (NASDAQ:COYA) Shares Acquired by Vanguard Group Inc. - Defense World
Coya Therapeutics, Inc. (NASDAQ:COYA) Forecasted to Earn FY2025 Earnings of ($1.26) Per Share - MarketBeat
Chardan Capital Weighs in on Coya Therapeutics, Inc.’s FY2025 Earnings (NASDAQ:COYA) - Defense World
Frontotemporal Dementia Market to Show Remarkable Growth - openPR
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - Manchestertimes
Coya Therapeutics Provides a Corporate Update and Reports Unaudited Second Quarter 2024 Financial Results - wallstreet:online
COYA Stock Earnings: Coya Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Stock Price Down 2.9% - Defense World
Coya Therapeutics Blunders on Test Results - MSN
Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com India
Coya reports Alzheimer's trial to present at CTAD24 - Investing.com
Coya reports Alzheimer's trial to present at CTAD24 By Investing.com - Investing.com Canada
Coya Therapeutics Blunders on Test Results - Baystreet.ca
Coya Therapeutics Announces that Results from a Double-Blind Placebo-Controlled Study in Alzheimer’s Disease will be presented on October 29, 2024 at the Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid - Chronicle-Tribune
Coya Therapeutics files for IP on novel therapy combination - Investing.com
Coya Therapeutics Expands Pipeline and Intellectual Property Portfolio with Filing of New U.S. Patents for COYA 301 in Combination with Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists - StockTitan
Long Term Trading Analysis for (COYA) - Stock Traders Daily
(COYA) Investment Report - Stock Traders Daily
Coya Shares Rise After Next Step to New Study of ALS Treatment - MarketWatch
Coya Therapeutics faces FDA hold on ALS drug study - Investing.com
individual investors who own 58% along with institutions invested in Coya Therapeutics, Inc. (NASDAQ:COYA) saw increase in their holdings value last week - Simply Wall St
Coya Therapeutics faces FDA hold on ALS drug study By Investing.com - Investing.com Canada
Coya Therapeutics (NASDAQ:COYA) Shares Down 2.7% - MarketBeat
Howard Berman, CEO and co-founder of Coya Therapeutics - InnovationMap
3 Houston health tech innovators to know this week - InnovationMap
Trend Tracker for (COYA) - Stock Traders Daily
Coya Therapeutics - The Pharma Letter
Coya extends research collaboration into exosomes from T-cells - Parkinson's News Today
Form 424B3 Coya Therapeutics, Inc. - StreetInsider.com
COYACoya Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Coya Therapeutics Expands Sponsored Research Collaboration with Houston Methodist Research Institute Along with ... - StockTitan
Investor's Toolkit: Key Ratios for Assessing Coya Therapeutics Inc (COYA)'s Performance – DWinneX - The Dwinnex
COYA 302 slows ALS progression, lowers biomarkers: Trial - ALS News Today
COYA 302 slows disease progression, lowers biomarkers: Trial - ALS News Today
Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 20.0% in May - MarketBeat
Coya Therapeutics (NASDAQ:COYA) Coverage Initiated by Analysts at Rodman & Renshaw - Defense World
Coya Therapeutics (NASDAQ:COYA) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Greenlight Capital Inc. Purchases 805,959 Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) - MarketBeat
New study: Promising breakthrough in slowing the progression of ALS - Digital Journal
Coya Therapeutics reports ALS treatment stability at 6 months - Investing.com India
Coya stock gains on potential of new ALS drug (NASDAQ:COYA) - Seeking Alpha
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology - Business Wire
Coya Therapeutics Announces Publication of ALS Study in Peer-Reviewed Journal Frontiers in Neurology - Yahoo Finance
Coya: Potential Milestone For The Treatment Of Alzheimer's - Seeking Alpha
Coya Therapeutics: Potential Milestone For The Treatment Of Alzheimer's This Summer - Seeking Alpha
Coya Therapeutics' (COYA) “Buy” Rating Reaffirmed at Chardan Capital - Defense World
Coya Therapeutics' (COYA) "Buy" Rating Reiterated at Chardan Capital - MarketBeat
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology - Marketscreener.com
1.25%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):